Petrelintide
A weekly amylin analogue tested on its own rather than paired with a GLP-1 drug, with a phase 2 obesity trial published in 2026
Amylin is the hormone the pancreas releases alongside insulin to signal fullness. Petrelintide is a long-acting version that can be formulated near neutral pH, which matters for mixing it with other drugs. It has finished phase 1 and a 42-week phase 2 in obesity.
What is it?
Amylin slows stomach emptying and signals fullness through receptors in the hindbrain, a pathway separate from GLP-1. Native amylin clumps in solution, which is why its first drug, pramlintide, had to be dosed separately from insulin. Petrelintide was engineered for chemical stability at about neutral pH, so it could in principle be mixed with other peptide drugs.
Phase 1 tested single doses from 0.04 to 2.4 mg and weekly doses escalated to 9 mg. It was well tolerated with no serious adverse events; gastrointestinal effects were the commonest, mostly mild, with nausea in 16.7% to 33.3% of participants depending on the cohort.
The phase 2 trial, ZUPREME 1, randomised 493 adults with obesity at 32 sites in Poland, Romania and the US to weekly maintenance doses of 1 to 9 mg or placebo for 42 weeks. Roche and Zealand reported up to 10.7% mean weight loss against 1.7% on placebo at week 42, using the efficacy estimand. It tests amylin agonism alone, as a distinct mechanism from the incretin drugs, rather than as half of a combination.
That makes petrelintide a counterpoint to cagrilintide, the other long-acting amylin analogue, which reached phase 3 only as part of the CagriSema combination with semaglutide. If amylin agonism alone proves enough for meaningful weight loss, it would offer a different mechanism to people who do not tolerate GLP-1 drugs. Petrelintide is not approved anywhere and no application appears in Drugs@FDA.
At a Glance
Every value in this table is printed from the Grey Peptides dataset, the same record the compound explorer and comparison tool read, so the three can never disagree.
Educational information, not medical advice. The doses on this page come from approved labels, published studies and, where no study exists, amounts reported by users. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose. Full medical disclaimer.
Published Research
These are the studies that describe petrelintide, read from their PubMed abstracts: the phase 2, the phase 1 trials and the development paper.
ZUPREME 1, the phase 2
Adults with obesity, or overweight with hypertension or dyslipidaemia, at 32 sites were randomised 5:1 to self-injected weekly petrelintide at maintenance doses of 1.0 to 9.0 mg or placebo for 42 weeks including dose escalation.
Two phase 1 trials
Single doses of 0.04 to 2.4 mg and weekly doses escalated to 9.0 mg were well tolerated with no serious adverse events. Gastrointestinal effects were commonest and mostly mild; nausea affected 16.7% to 33.3% of participants by cohort.
How it was designed
The development paper describes optimising chemical stability so the analogue can be formulated at about neutral pH while keeping its potency in cells and animals, which is what would allow co-formulation with other drugs.
Side Effects & Contraindications
Reported Side Effects
From the phase 1 trials; phase 2 safety is in the trial report.
Contraindications & Cautions
An investigational drug available only in trials.
Legal Status
Petrelintide is investigational everywhere.
Frequently Asked Questions
?What is petrelintide?
A long-acting analogue of amylin, the fullness hormone the pancreas releases alongside insulin, given once weekly.
?How is it different from cagrilintide?
Both are long-acting amylin analogues. Cagrilintide reached phase 3 paired with semaglutide; petrelintide's phase 2 tests it alone.
?Is it safe?
Phase 1 found no serious adverse events, with mostly mild gastrointestinal effects. Longer safety data come from the phase 2.
?Is it approved?
No. It is investigational, and no application appears in Drugs@FDA.
References
- [pubmed] Garvey WT, et al. "Petrelintide, a human amylin analogue for the treatment of obesity (ZUPREME 1): a randomised, double-blind, placebo-controlled, phase 2 trial." Lancet Diabetes Endocrinol, 2026. PMID: 42810355.
- [pubmed] Brændholt Olsen M, et al. "Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Petrelintide for Weight Management: Two Randomized, Controlled Phase 1 Trials." Diabetes Obes Metab, 2026;28(7):5915-5925. PMID: 42017294.
- [pubmed] Fischer Munch H, et al. "Development of Petrelintide: a Potent, Stable, Long-Acting Human Amylin Analogue." J Med Chem, 2025;68(22):23925-23940. PMID: 41217931.
- [other] US FDA, Drugs@FDA (openFDA): no application for petrelintide. Read September 30, 2026.
- [other] Roche, press release, March 5, 2026: positive topline results from the phase II ZUPREME-1 trial (NCT06662539) in 493 people with overweight or obesity, up to 10.7% mean weight loss at week 42 (efficacy estimand) against 1.7% on placebo; the release also notes the 2025 Roche-Zealand collaboration. Read September 30, 2026.
- [other] Zealand Pharma, press release, March 5, 2026: positive phase 2 results for petrelintide in ZUPREME-1; ZUPREME-2 in people with type 2 diabetes reporting in the second half of 2026. Read September 30, 2026.
Sources & Citations
Studies were read from their PubMed records; regulatory sources are listed below, read September 30, 2026.
Medical Disclaimer: This content is for educational and informational purposes only. It is not medical advice, and nothing here is an instruction to obtain or use any compound. Consult a licensed healthcare provider before making health decisions.